- Home
- GAME vs ALXO Comparison
GAME vs ALXO Comparison
Compare GAME & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- ALXO
- Stock Information
- Founded
- GAME 2011
- ALXO 2015
- Country
- GAME United States
- ALXO United States
- Employees
- GAME N/A
- ALXO N/A
- Industry
- GAME
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- ALXO Health Care
- Exchange
- GAME Nasdaq
- ALXO Nasdaq
- Market Cap
- GAME 27.2M
- ALXO 28.3M
- IPO Year
- GAME 2009
- ALXO 2020
- Fundamental
- Price
- GAME $0.67
- ALXO $0.46
- Analyst Decision
- GAME Strong Buy
- ALXO Strong Buy
- Analyst Count
- GAME 3
- ALXO 6
- Target Price
- GAME $3.67
- ALXO $3.54
- AVG Volume (30 Days)
- GAME 271.0K
- ALXO 512.2K
- Earning Date
- GAME 05-15-2025
- ALXO 05-08-2025
- Dividend Yield
- GAME N/A
- ALXO N/A
- EPS Growth
- GAME N/A
- ALXO N/A
- EPS
- GAME N/A
- ALXO N/A
- Revenue
- GAME $96,198,101.00
- ALXO N/A
- Revenue This Year
- GAME $14.34
- ALXO N/A
- Revenue Next Year
- GAME $24.00
- ALXO N/A
- P/E Ratio
- GAME N/A
- ALXO N/A
- Revenue Growth
- GAME 132.91
- ALXO N/A
- 52 Week Low
- GAME $0.50
- ALXO $0.44
- 52 Week High
- GAME $1.64
- ALXO $17.50
- Technical
- Relative Strength Index (RSI)
- GAME 48.38
- ALXO 38.73
- Support Level
- GAME $0.60
- ALXO $0.41
- Resistance Level
- GAME $0.69
- ALXO $0.55
- Average True Range (ATR)
- GAME 0.07
- ALXO 0.05
- MACD
- GAME -0.01
- ALXO 0.00
- Stochastic Oscillator
- GAME 28.71
- ALXO 22.76
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.